According to Jefferies, Bio-Rad Laboratories BIO reaffirmed its formal 2011 organic revenue growth outlook of ~5%.
Jefferies said that adjusted 2Q11 EPS of $1.41 was $0.06 below consensus as a higher tax rate (-$0.07) offset a better than expected revenue growth experience. The 2011 EPS forecast ($6.15) and price target ($145) are unchanged. “Our $145 PT represents a 10-year discount horizon in our DCF model and implies an EV of 8.5x our 2012 EBITDA forecast. Risks: margin expansion progress, ERP implementation.”
Bio-Rad Laboratories closed yesterday at $103.65.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in